1.93
price up icon4.89%   0.09
after-market After Hours: 1.91 -0.02 -1.04%
loading
Soligenix Inc stock is traded at $1.93, with a volume of 32,687. It is up +4.89% in the last 24 hours and up +2.12% over the past month. Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).
See More
Previous Close:
$1.84
Open:
$1.84
24h Volume:
32,687
Relative Volume:
0.43
Market Cap:
$6.17M
Revenue:
$960.60K
Net Income/Loss:
$-7.10M
P/E Ratio:
-0.2553
EPS:
-7.56
Net Cash Flow:
$-8.00M
1W Performance:
+2.12%
1M Performance:
+2.12%
6M Performance:
-40.25%
1Y Performance:
-53.49%
1-Day Range:
Value
$1.84
$1.94
1-Week Range:
Value
$1.84
$1.9676
52-Week Range:
Value
$1.68
$14.83

Soligenix Inc Stock (SNGX) Company Profile

Name
Name
Soligenix Inc
Name
Phone
609-538-8200
Name
Address
29 EMMONS DRIVE, PRINCETON
Name
Employee
16
Name
Twitter
@Soligenix_Inc
Name
Next Earnings Date
2024-11-11
Name
Latest SEC Filings
Name
SNGX's Discussions on Twitter

Compare SNGX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
SNGX
Soligenix Inc
1.93 6.17M 960.60K -7.10M -8.00M -7.56
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
450.50 113.52B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
493.22 52.93B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
300.83 39.71B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
585.93 35.00B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
255.86 26.57B 3.81B -644.79M -669.77M -6.24

Soligenix Inc Stock (SNGX) Upgrades & Downgrades

Date Action Analyst Rating Change
Jul-28-20 Downgrade Dawson James Buy → Neutral
Jan-31-18 Downgrade H.C. Wainwright Buy → Neutral
Aug-14-17 Reiterated Maxim Group Buy
Jul-17-17 Initiated H.C. Wainwright Buy

Soligenix Inc Stock (SNGX) Latest News

pulisher
Jun 06, 2025

Soligenix Highlights Dr. Ellen Kim's Recent Q&A and the Promise - GuruFocus

Jun 06, 2025
pulisher
Jun 06, 2025

Soligenix Highlights Dr. Ellen Kim’s Recent Q&A and the Promise of HyBryte™ in Ongoing Clinical Trials - GlobeNewswire

Jun 06, 2025
pulisher
Jun 04, 2025

Soligenix Inc. (SNGX) Showcases Promising HyBryte Results in CTCL Treatment Through New Podcast - citybuzz -

Jun 04, 2025
pulisher
May 27, 2025

Soligenix (NASDAQ: SNGX) Innovative Treatment to Combat Bacterial Infection Fills Urgent Need for Alternatives to Antibiotics - Barchart.com

May 27, 2025
pulisher
May 27, 2025

Vaccine Contract Manufacturing Market Is Booming Worldwide | - openPR.com

May 27, 2025
pulisher
May 23, 2025

Soligenix’s (NASDAQ: SNGX) HyBryte(TM) Delivers Strong Results In Rare Cancer Trial - Barchart.com

May 23, 2025
pulisher
May 23, 2025

Stocks in play: Brookfield Corporation - The Globe and Mail

May 23, 2025
pulisher
May 23, 2025

Soligenix’s (NASDAQ: SNGX) HyBryte(TM) Delivers Strong Results in Rare Cancer Trial - The Globe and Mail

May 23, 2025
pulisher
May 22, 2025

Chemung Financial Corporation Announces Quarterly Dividend - The Globe and Mail

May 22, 2025
pulisher
May 22, 2025

Soligenix’s HyBryte Shows Promise in Rare Cancer Treatment - citybuzz -

May 22, 2025
pulisher
May 20, 2025

Soligenix (NASDAQ: SNGX) Reports Q1 Milestones, Financial Results - The Globe and Mail

May 20, 2025
pulisher
May 20, 2025

/R E P E A T -- Scotiabank to Announce Second Quarter 2025 Results/ - The Globe and Mail

May 20, 2025
pulisher
May 20, 2025

Public market insider selling at Sprott (SII) - The Globe and Mail

May 20, 2025
pulisher
May 19, 2025

Photodynamic Therapy Market Trends Report 2025-2033, Competitive Analysis of Gladerma, Sun Pharma, Biofrontera, Lumibird, Bausch Health, Soligenix, Modulight, and Theralase TechnologiesResearchAndMarkets.com | FinancialContent - FinancialContent

May 19, 2025
pulisher
May 18, 2025

Zacks Small Cap Predicts Reduced Earnings for Soligenix - Defense World

May 18, 2025
pulisher
May 16, 2025

Zacks Research Issues Business Update as Soligenix (NASDAQ: SNGX) Continues Enrollment in Confirmatory Phase 3 HyBryte Trial - The Globe and Mail

May 16, 2025
pulisher
May 16, 2025

Oral Mucositis Drugs Market Set to Witness Significant Growth - openPR.com

May 16, 2025
pulisher
May 15, 2025

SNGX: Enrollment Continues in Confirmatory Phase 3 Trial of HyBryte™ in CTCL… - MSN

May 15, 2025
pulisher
May 15, 2025

Soligenix Reports Q1 2025 Financial Results and Milestones - TipRanks

May 15, 2025
pulisher
May 13, 2025

SNGX: Enrollment Continues in Confirmatory Phase 3 Trial of HyBryte in CTCL - Research Tree

May 13, 2025
pulisher
May 12, 2025

Contrasting Schrödinger (NASDAQ:SDGR) and Soligenix (NASDAQ:SNGX) - Defense World

May 12, 2025
pulisher
May 10, 2025

Soligenix Announces Recent Accomplishments And First Quarter 2025 Financial Results - Nasdaq

May 10, 2025
pulisher
May 09, 2025

Soligenix Announces Recent Accomplishments And First Quarter 202 - GuruFocus

May 09, 2025
pulisher
May 07, 2025

Soligenix (NASDAQ: SNGX) CEO Highlights Pipeline and Strategy in BioMedWire Podcast Episode - The Globe and Mail

May 07, 2025
pulisher
May 07, 2025

IBN Announces Latest Episode of The BioMedWire Podcast Featuring Dr. Christopher Schaber, CEO of Soligenix Inc. - The Manila Times

May 07, 2025
pulisher
May 05, 2025

Geode Capital Management LLC Has $71,000 Stake in Soligenix, Inc. (NASDAQ:SNGX) - Defense World

May 05, 2025
pulisher
May 02, 2025

Soligenix (NASDAQ: SNGX) HyBryte(TM) Paves Way for Breakthrough Treatment for Rare Skin Cancer - Barchart.com

May 02, 2025
pulisher
May 02, 2025

Soligenix (SNGX) Projected to Post Quarterly Earnings on Friday - Defense World

May 02, 2025
pulisher
Apr 30, 2025

Soligenix (NASDAQ: SNGX) Moves Forward To Strengthen The Case For HyBryte(TM) - Barchart.com

Apr 30, 2025
pulisher
Apr 30, 2025

Soligenix (NASDAQ: SNGX) Moves Forward to Strengthen the Case for HyBryte(TM) - The Globe and Mail

Apr 30, 2025
pulisher
Apr 25, 2025

U.S. Severe Oral Mucositis Market Projected To Witness - openPR.com

Apr 25, 2025
pulisher
Apr 24, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 24, 2025
pulisher
Apr 24, 2025

Soligenix reports positive results in skin cancer treatment trial By Investing.com - Investing.com India

Apr 24, 2025
pulisher
Apr 24, 2025

Fireside Chat with Christopher Schaber, Chief Executive Officer of Soligenix, Inc. - Yahoo Finance

Apr 24, 2025
pulisher
Apr 24, 2025

Soligenix reports positive results in skin cancer treatment trial - Investing.com Australia

Apr 24, 2025
pulisher
Apr 24, 2025

Solgenix shares rise on positive skin cancer treatment results By Investing.com - Investing.com Canada

Apr 24, 2025
pulisher
Apr 24, 2025

Soligenix's HyBryte(TM) Shows 75% Response Rate In Skin Cancer Trial, Backed By FDA Funding - The Globe and Mail

Apr 24, 2025
pulisher
Apr 23, 2025

EQS-News: Soligenix's HyBryte(TM) Shows 75% Response Rate In Skin Cancer Trial, Backed By FDA Funding - markets.businessinsider.com

Apr 23, 2025
pulisher
Apr 22, 2025

Soligenix (NASDAQ: SNGX) Advances CiVax Amid Ongoing COVID-19 Threat - Barchart.com

Apr 22, 2025
pulisher
Apr 15, 2025

Soligenix (NASDAQ: SNGX) Announces Positive Data, Continued Advancement of HyBryte(TM) - The Globe and Mail

Apr 15, 2025
pulisher
Apr 15, 2025

Positive Outcome in 75% of CTCL Patients Treated with HyBryte™ f - GuruFocus

Apr 15, 2025
pulisher
Apr 14, 2025

SNGX: Updated IIS Data Shows 75% Response Rate and Three Complete Responses… - MSN

Apr 14, 2025
pulisher
Apr 14, 2025

Soligenix Announces Positive Data For Extended HyBryte In Early-stage Cutaneous T-cell Lymphoma - Nasdaq

Apr 14, 2025
pulisher
Apr 14, 2025

Soligenix (SNGX) Reports Promising Interim Results for HyBryte i - GuruFocus

Apr 14, 2025

Soligenix Inc Stock (SNGX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$73.62
price up icon 1.21%
$22.20
price up icon 1.79%
$20.59
price up icon 4.36%
$33.78
price up icon 0.09%
$108.49
price down icon 1.51%
biotechnology ONC
$255.86
price down icon 0.44%
Cap:     |  Volume (24h):